Edgewise TherapeuticsvsJohnson & Johnson

EWTX and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

EWTX

Edgewise Therapeutics, Inc.

$42.04

Value $4.5B

-3.75%
EWTX's page

Edgewise Therapeutics (EWTX) has a market value of $4.5B and Johnson & Johnson (JNJ) $672B. Over the last year, with dividends, EWTX moved +84.8% and JNJ +45.4%. The P/E is 4.5 for EWTX and 41.7 for JNJ. Dividend yield: EWTX none, JNJ 1.89%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    EWTX$4.5B

    JNJ$672B

    JNJ is 149 times EWTX

  • Revenue, 12 months

    EWTX–

    JNJ$99.3B

  • Net income, 12 months

    EWTX$1.0B

    JNJ$16.1B

    JNJ is 16 times EWTX

  • Operating margin

    EWTX–

    JNJ–

  • ROIC

    EWTX-29.0%

    JNJ12.4%

    41.3 points apart

  • P/E

    EWTX4.5

    JNJ41.7

    JNJ is 9.3 times EWTX

  • Dividend yield

    EWTX0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    EWTX+107.2%

    JNJ+97.0%

    10.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

EWTX+107.2%

JNJ+96.9%

10020020222023202420252026
Returns by period
PeriodEWTXWith dividendsJNJWith dividends
1 year since November 14, 2025+84.8%Price +84.8%+45.4%Price +42.2%
3 years since November 17, 2023+557.9%+87.4% a yearPrice +557.9%+102.6%+26.5% a yearPrice +86.1%
5 years since November 16, 2021+107.2%+15.7% a yearPrice +107.2%+97.0%+14.5% a yearPrice +71.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

EWTXEdgewise TherapeuticsJNJJohnson & Johnson

Valuation

EWTXJNJ
Valuation
Price$42.04$278.70
Market value$4.5B$672B
Enterprise value (EV)$3.3B$699B
P/E4.541.7
P/E, 5-year median–21.9
P/B2.88.2
EV/EBIT–39.4
Free cash flow yield–3.1%

Results and growth

EWTXJNJ
Results and growth
Revenue, 12 months–$99.3B
Net income, 12 months$1.0B$16.1B
Free cash flow, 12 months-$202M$20.6B
Earnings per share, 12 months$9.41$6.59
Revenue growth, year on year–6.1%
Revenue growth a year, past–+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

EWTXJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin––
Net margin–16.2%
ROIC-29.0%12.4%
ROE138.1%19.7%

Balance sheet

EWTXJNJ
Balance sheet
Cash$1.2B$17.2B
Total debt$3.4M$44.7B
Net debt / EBITDA–1.1
Interest cover–18.0×

Dividends and buybacks

EWTXJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: EWTX or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Edgewise Therapeutics or Johnson & Johnson?

By market value, Johnson & Johnson ($672B) is about 148.9 times Edgewise Therapeutics ($4.5B), at today's prices.

How did EWTX and JNJ stock do over the last 5 years?

Since November 16, 2021, EWTX's price moved +107.2% and JNJ's +71.3%. With dividends: EWTX +107.2% (+15.7% a year), JNJ +97.0% (+14.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, EWTX or JNJ?

The dividend yield at today's price is none for Edgewise Therapeutics and 1.89% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

What is the P/E of EWTX and JNJ?

At today's price, the P/E is 4.5 for EWTX and 41.7 for JNJ. It is the share price over the last twelve months' earnings per share.

Which is the better investment, Edgewise Therapeutics or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.